Viskase Holdings, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was North America at $36.8 million, 39% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Nojax Product Line at $53.8 million, 57% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
272
|
95
|
90
|
87
|
—
|
—
|
—
|
—
|
0
|
| Operating segments | |||||||||
| North America |
—
|
37
+13.5%
share 38.6%
|
36
-12.1%
share 40.2%
|
33
-23.2%
share 38.6%
|
—
|
32
|
41
|
43
|
—
|
| Emea |
—
|
34
-8.3%
share 36.1%
|
34
+0.6%
share 38.1%
|
34
+12.9%
share 39.2%
|
—
|
38
|
34
|
30
|
—
|
| South America |
—
|
14
+21.6%
share 14.6%
|
11
-4.8%
share 12.2%
|
11
+0.6%
share 13.2%
|
—
|
11
|
12
|
11
|
—
|
| Asia |
—
|
10
+3.8%
share 10.7%
|
9
-17.7%
share 9.5%
|
8
-15.9%
share 9.1%
|
—
|
10
|
10
|
9
|
—
|
| Sales mix | |||||||||
| Nojax Product Line |
—
|
54
+14.3%
share 56.5%
|
50
-1.8%
share 55.3%
|
47
-10.4%
share 54.0%
|
—
|
47
|
51
|
52
|
—
|
| Fibrous Product Line |
—
|
22
-17.7%
share 23.6%
|
25
-12.1%
share 27.3%
|
25
-2.1%
share 28.5%
|
—
|
27
|
28
|
25
|
—
|
| Plastic Product Line |
—
|
11
-8.0%
share 11.3%
|
11
-13.2%
share 12.0%
|
11
-13.1%
share 12.4%
|
—
|
12
|
12
|
12
|
—
|
| Other Product Line |
—
|
3
+411.7%
share 3.5%
|
0
-87.3%
share 0.3%
|
1
+2627.6%
share 0.8%
|
—
|
1
|
2
|
-0
|
—
|
| Traded Goods Product Line |
—
|
3
share 2.8%
|
—
|
2
+1.4%
share 2.3%
|
—
|
—
|
2
|
2
|
—
|
| Large Product Line |
—
|
2
+22.0%
share 2.4%
|
2
+10.8%
share 2.4%
|
2
-35.7%
share 1.9%
|
—
|
2
|
2
|
3
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VISK (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lombard, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 727510
- Former names
- ENZON PHARMACEUTICALS, INC. (until Mar 25, 2026); ENZON PHARMACEUTICALS INC (until Feb 23, 2016); ENZON PHARMACEUTICALS INC (until Mar 22, 2006); ENZON PHARMACEUTICAL INC (until Dec 10, 2002); ENZON INC (until Dec 9, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.